Under the terms, Ligand will pay $39 a share in cash for Xoma, a 2.9% premium over the $37.90 closing price on Friday. The deal is expected to close in the third quarter.
Ligand Pharmaceuticals continues to outperform, driven by its high-margin, diversified royalty model and disciplined investment approach. LGND’s transition in 2022 to a capital and technology provider ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results